The in vivo experiment will also bring the study to a full circle starting from recognizing CD24 as a marker of cisplatin resistant population in vitro to screening for CD24 in pre-cisplatin treatment patient tumor samples, to treating tumors induced with CD24 modulated cell lines with cisplatin treatment. This evidence concerns the gene CD24 and neoplasm.